RAPP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Rapport Therapeutics Inc (RAPP) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock shows strong technical indicators, positive analyst ratings, and promising clinical trial potential, making it a compelling long-term opportunity.
The stock exhibits bullish technical indicators. The MACD is positive and expanding (0.202), RSI is neutral at 59.005, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 25.69, and resistance is at 28.578, with the pre-market price of 27.5 indicating proximity to resistance levels. The stock trend analysis suggests a 90% chance of a 12.98% increase in the next month.
Analysts have initiated coverage with high confidence in the company's Phase 3 trials for RAP-219, with price targets of $43 and $
The company's clinical data suggests 'best-in-category efficacy' potential.
Stock trend analysis indicates a high probability of upward movement in the next month.
No recent news or significant hedge fund/insider trading activity.
Financials show no revenue and negative net income, though losses have narrowed YoY.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$26.93M, which improved by 53.53% YoY. EPS improved to -0.71, up 42% YoY. The company remains in the clinical stage with no revenue generation yet.
Analysts from Wells Fargo and BTIG have initiated coverage with Overweight/Buy ratings and price targets of $43 and $47, citing confidence in Phase 3 trials and approval potential for RAP-219.
